- Entry
- $3.88
- Final
- $1.71 -55.9%
- Target
- —
- Score
- -1.00
Most investors look at Lantern Pharma as a small oncology biotech. But what if the market is missing the platform value? Lantern today has: • LP-300 in Phase 2 for never-smoker NSCLC (HARMONIC trial)  • LP-184 advancing across multiple solid tumors and CNS cancers, including GBM, pancreatic cancer and brain metastases  • LP-284 in clinical development for relapsed/refractory lymphomas  • An ADC program in development  • The proprietary RADR® AI platform, used to identify patient populations, …
— ORIGINAL POST ·
Lantern Pharma ($LTRN): Why Is the Market Valuing an AI Oncology Platform at Only $50M?
· r/investing
· Jun 13, 2026